1877 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Junshi Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$12.98 |
| 52 Week High | HK$24.60 |
| 52 Week Low | HK$9.17 |
| Beta | 0.41 |
| 11 Month Change | -9.99% |
| 3 Month Change | 10.00% |
| 1 Year Change | -43.19% |
| 33 Year Change | -72.47% |
| 5 Year Change | -49.88% |
| Change since IPO | -45.35% |
Recent News & Updates
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Oct 14
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Sep 30Recent updates
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Oct 14Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Sep 30Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors
Aug 29Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?
Jun 28Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth
May 06Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jan 16Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 03Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Oct 12Shareholder Returns
| 1877 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 1.6% | 1.5% | 0.4% |
| 1Y | -43.2% | -11.2% | 12.0% |
Return vs Industry: 1877 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 1877 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 1877 volatility | |
|---|---|
| 1877 Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1877 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1877's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,532 | Cong Li | www.junshipharma.com |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People’s Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People’s Republic of China.
Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary
| 1877 fundamental statistics | |
|---|---|
| Market cap | HK$27.93b |
| Earnings (TTM) | -HK$1.94b |
| Revenue (TTM) | HK$1.92b |
6.7x
P/S Ratio-6.6x
P/E RatioIs 1877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1877 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.79b |
| Cost of Revenue | CN¥622.89m |
| Gross Profit | CN¥1.16b |
| Other Expenses | CN¥2.97b |
| Earnings | -CN¥1.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | 65.15% |
| Net Profit Margin | -100.90% |
| Debt/Equity Ratio | 43.8% |
How did 1877 perform over the long term?
See historical performance and comparison